Tag: agreement

TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- ZOOZ Strategy Ltd. (Nasdaq and TASE: ZOOZ) (“ZOOZ” or the “Company”) today announced that its Board of Directors has authorized management to explore a range of strategic alternatives that could potentially complement the Company’s existing bitcoin treasury strategy and enhance long-term shareholder value.

AS PRFoods (registry code 11560713) hereby notifies that its subsidiary Saaremere Kala AS (registry code  11310040, hereinafter "Seller") has completed previously announced transaction (as disclosed in a stock exchange announcement published by AS PRFoods on 23 April 2026 (https://view.news.eu.nasdaq.com/view?id=1436682&lang=en), whereby 100% shareholding in Saare Kala Tootmine OÜ (registry code 10377013, hereinafter "SKT") was sold and claims arising from shareholder loans and an inventory loan provided to SKT were transferred to the Latvian company Brīvais Vilnis A/S (Latvian registry code: 40003056186, hereinafter "Buyer"). The general meeting of shareholders of AS PRFoods approved the transaction by their relevant resolution published on 18 May 2026 (https://view.news.eu.nasdaq.com/view?id=1442522&lang=en). In accordance with the terms of the transaction, the vendor note agreement concluded between the Seller and the Buyer and setting out the terms of the payment by the Buyer to the Seller of the amount equal to the outstanding purchase price for the share of SKT and of the transfer price for the inventory loans has entered into force upon completion of the transaction.

TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the closing of Teva’s acquisition of Emalex Biosciences, strengthening its late-stage pipeline with ecopipam and further advancing its Pivot to Growth strategy. Phase 3 data for ecopipam were recently published in JAMA Neurology, and a U.S. NDA submission is anticipated in the second half of 2026.